#informationmanagement

L3Harris Technologies, Inc. (LHX) has a notice of proposed sale filed under Rule 144 for common stock held for the benefit of officer Christopher Kubasik. The notice covers planned sales totaling 21,916 shares of common stock through Goldman Sachs & Co. LLC as broker.

The securities to be sold were acquired as compensation through multiple Restricted Stock Unit grants from 2018 and 2019, including awards dated December 14, 2018 and June 29, 2019. The filing states that 7,411 shares are to be sold by KUBASIK, C GRAT BKG 2025 1.0 and 14,505 shares by KUBASIK, C GRAT BKG 2024 5.0.

It discloses a planned resale of 21,916 L3Harris (LHX) common shares for the account of officer Christopher Kubasik under Rule 144, with Goldman Sachs & Co. LLC acting as broker and the shares originally acquired as compensation via Restricted Stock Units.

The filing states that 7,411 shares are to be sold by KUBASIK, C GRAT BKG 2025 1.0 and 14,505 shares are to be sold by KUBASIK, C GRAT BKG 2024 5.0, together accounting for the 21,916 shares covered by the notice.

The common shares to be sold were acquired as compensation through several Restricted Stock Unit grants from L3Harris Technologies, Inc., including grants dated December 14, 2018, February 11, 2019, February 16, 2019, and June 29, 2019.

The planned sales of L3Harris (LHX) common stock are to be handled by Goldman Sachs & Co. LLC, listed with its New York address, as the broker in the Form 144 securities information section.

The securities information section lists an aggregate market value of 5,443,276.92 for the L3Harris common stock covered by the notice, along with 186,214,616 shares shown as outstanding for the issuer.

The notice is dated September 10, 2026, which appears both as the date in the securities information section and as the Date of Notice in the remarks and signature portion of the filing.

https://www.sec.gov/Archives/edgar/data/202058/000195824426000587/xsl144X01/primary_doc.xml

Humana's most severe legal and ethical controversies involve systemic denial of patient care using flawed predictive algorithms and major Medicare fraud settlements. Critics and lawsuits target its utilization of automated tools to prematurely cut off necessary rehabilitation and nursing care for elderly patients, alongside multi-million dollar federal fraud recoveries.

Systematic Care Denials via Algorithms

• The nH Predict Tool: Humana faced major class-action lawsuits for using an algorithmic model called nH Predict (developed by NaviHealth) to systematically forecast and cut off coverage for post-acute rehabilitation and skilled nursing facility care.
• Impact on Patients: Lawsuits allege the algorithm superseded individual doctor evaluations, leading to wrongful, repetitive denials of medically necessary care for vulnerable seniors who were forced to pay out-of-pocket or forego treatment.

Medicare and Billing Fraud Settlements

• Part D Bid Fraud ($90 Million Settlement): Humana paid $90 million to resolve a landmark whistleblower lawsuit brought by a former actuary. The suit accused Humana of keeping two sets of books and submitting fraudulent, inflated bids to the Centers for Medicare & Medicaid Services (CMS) for prescription dr-g contracts from 2011 to 2017.
• Overcharging Federal Audits: Federal audits by the Office of Inspector General (OIG) have repeatedly caught Humana overcharging Medicare by tens to hundreds of millions of dollars through unsupported risk-adjustment diagnoses.

What GBCs will be gone after Polaris? Any information helps. Even though we’re cheap, can’t compete with MC’s india strategy.

Anyone else dealing with a manager who treats information like it’s classified? Getting even the simplest thing feels like pulling teeth. At this point, I’m losing more time chasing answers than actually doing the work.

what does this mean?